Deirdre Somers Sells 1,637 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers sold 1,637 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.53, for a total value of $17,237.61. Following the transaction, the director now directly owns 41,675 shares of the company’s stock, valued at approximately $438,837.75. The trade was a 3.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Enfusion Price Performance

NYSE ENFN traded up $0.10 on Wednesday, reaching $10.91. The company had a trading volume of 1,645,948 shares, compared to its average volume of 1,406,472. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of 272.82, a P/E/G ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a fifty-two week low of $7.52 and a fifty-two week high of $11.38. The business has a 50 day moving average of $10.19 and a two-hundred day moving average of $9.23.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Stifel Nicolaus raised their target price on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday. Finally, Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Enfusion currently has a consensus rating of “Hold” and a consensus price target of $10.25.

Institutional Investors Weigh In On Enfusion

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Centiva Capital LP increased its position in Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after purchasing an additional 1,227 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the period. Azora Capital LP lifted its holdings in Enfusion by 6.8% in the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after buying an additional 1,890 shares during the period. 272 Capital LP grew its holdings in Enfusion by 1.5% during the 2nd quarter. 272 Capital LP now owns 139,180 shares of the company’s stock worth $1,186,000 after acquiring an additional 2,000 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after acquiring an additional 4,239 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.